Rationale for the Use of Aromasin with Tamoxifen During Post
Cycle Therapy
by
Anthony Roberts
Author of
Anabolic Steroids: Ultimate Research Guide and
Beyond Steroids;
Co-Author with Christian Thibaudeau of
Dr. Jekyll and Mr. Hyde
- Body Transformation From Both Sides of
the Force
Anthony Roberts has been researching anabolic steroids for over a
decade. He recently began formulating dietary supplements for
bodybuilder. The first is
MyoGenX - a natural testosterone booster developed by world
famous steroid guru Anthony Roberts. MyoGenX contains a three
pronged attack scientifically proven to increase your testosterone
levels - which will in turn increase your lean muscle mass, boost
your strength, and burn your fat!
Publication Date:
November 11, 2005
Discussion of pharmaceutical agents below is presented for
information only. Nothing here is meant to take the place of advice
from a licensed health care practitioner. Consult a physician before
taking any medication.
Aromasin (Exemestane) is one of those
weird compounds that nobody really knows what to do with. What we
generally hear about it makes it very uninteresting…It’s a third
generation Aromatase Inhibitor (AI) just like
Arimidex (Anastrozole) and Femera (Letrozole). Both of those two
drugs are very efficient at stopping the conversion of androgens into
estrogen, and since we have them, why bother with Aromasin? It’s a
little harder to get than the other two commonly used aromatase
inhibitors, because it’s not in high demand, and there’s never been a
readily apparent advantage to using it. And I mean…lets face it: It’s
awkward-sounding. Aromasin doesn’t have much of a ring to it, and
exemestane is even worse. Arimidex has a bunch of cool abbreviations
("A-dex" or just ‘dex) and even Letrozole is just "Letro" to most
people. Where’s the cool nickname for
Aromasin/exemestane? A-Sin? E-Stane?
It just doesn’t work. It’s the black sheep of AIs. And why do we even
need it when we have Letrozole, which is by far the most efficient AI
for stopping aromatization (the process by which your body converts
testosterone into estrogen)? Letro can reduce estrogen levels by 98% or
greater; clinically a dose as low as 100mcgs has been shown to provide
maximum aromatase inhibition (2)!
So why would we need any other AIs?
Well, first of all, estrogen is necessary for healthy joints (3) as well
as a healthy immune system (4). So getting rid of 98% of the estrogen in
your body for an extended period of time may not be the best of ideas.
This may be useful on an extreme cutting cycle, leading up to a
bodybuilding contest, or if you are particularly prone to gyno, but
certainly can’t be used safely for extended periods of time without
compromising your joints and immune system.
That leaves us with Arimidex, which isn’t as potent as Letrozole,
but at .5mgs/day will still get rid of around half (50%) of the estrogen
in your body. Problem solved, right? Use Arimidex on your typical
cycles, and if you are very prone to gyno or are getting ready for a
contest, use Letro.
But what about Post Cycle Therapy (PCT)?
I think at this point most people are sold on the use of
Nolvadex (Tamoxifen Citrate) instead of
Clomid for
post cycle therapy (PCT), since both compete estrogen at
the receptor site, both increase serum test levels, and both drugs may
also alter blood lipid profiles favorably (6). But since 20mgs of Tamoxifen is equal to 150mgs of clomid for purposes of testosterone
elevation, FSH and LH, but Tamoxifen doesn’t decrease the LH response to
LHRH (6) I think most people agree to Nolvadex’s superiority for PCT.
Aromasin with Nolvadex
I’ve always been in favor of using Nolvadex during PCT, along with an
AI, because reducing estrogen levels has been positively correlated with
an increase in testosterone (7) so in my mind, it’s be beneficial to
increase testosterone by as many mechanisms as possible while trying to
recover your endogenous testosterone levels after a cycle. SO which AI
do we use? Letro or A-dex? Well, why don’t we just keep using whichever
one we used during the cycle, and add in some Nolvadex? Unfortunately,
Nolvadex will significantly reduce the blood plasma levels of both
Letrozole as well as Arimidex (8). So if we choose to use one of them
with our Nolvadex on PCT, we’re throwing away a bit of money as the
Nolvadex will be reducing their effectiveness.
This, of course, is where Aromasin comes in, at 20-25mgs/day.
Aromasin, at that dose, will raise your testosterone levels by about
60%, and also help out your free to bound testosterone ratio by lowering
levels of Sex Hormone Binding Globulin (SHBG), by about 20% (12)…SHBG is
that nasty enzyme that binds to testosterone and renders it useless for
building muscle. But what about using it along with Nolvadex for PCT?
Difference Between Type-I and Type-II Aromatase Inhibitors
To understand why Aromasin may be useful in conjunction with Nolvadex
while both Letro and A-dex suffer reduced effectiveness, we’ll need to
first understand the differences between a Type-I and Type-II Aromatase
Inhibitor. Type I inhibitors (like Aromasin) are actually steroidal
compounds, while type II inhibitors (like Letro and A-dex)
are non-steroidal drugs. Hence, androgenic side effects are very
possible with Type-I AIs, and they should probably be avoided by women.
Of course, there are some similarities between the two types of AIs…both
type I & type II AIs mimic normal substrates (essentially
androgens), allowing them to compete with the substrate for access
to the binding site on the aromatase enzyme. After this binding,
the next step is where things differ greatly for the two
different types of AI’s. In the case of a type-I AI, the noncompetitive
inhibitor will bind, and the enzyme initiates a sequence of
hydroxylation; this hydroxylation produces an unbreakable covalent bond
between the inhibitor and the enzyme protein. Now, enzyme
activity is permanently blocked; even if all unattached inhibitor is
removed. Aromatase enzyme activity can only be restored by
new enzyme synthesis. Now, on the other hand, competitive inhibitors,
called type II AI’s, reversibly bind to the active enzyme
site, and one of two things can happen: 1.) either no enzyme activity is
triggered or 2.) the enzyme is somehow triggered without
effect. The type II inhibitor can now actually disassociate from the
binding site, eventually allowing renewed competition between the
inhibitor and the substrate for binding to the site. This
means that the effectiveness of competitive aromatase inhibitors depends
on the relative concentrations and affinities of both the
inhibitor and the substrate, while this is not so for noncompetitive
inhibitors. Aromasin is a type-I inhibitor, meaning that once it has
done its job, and deactivated the aromatase enzyme, we don’t need it
anymore. Letrozole and Arimidex actually need to remain present to
continue their effects. This is possibly why Nolvadex does not alter the
pharmacokinetics of Aromasin (11).
Conclusion
Before we close the book on Aromasin, it’s worth noting that you can
(and should) still use one of the non-steroidal AIs during your cycle to
reduce estrogen, if necessary. When you are ready for PCT, you can then
switch over to Aromasin and still experience the full effects of an AI,
since there is no cross-over tolerance experienced between steroidal and
non-steroidal AIs (9). Since Aromasin is about 65% efficient at
suppressing estrogen (10), it’s certainly a very powerful agent,
especially considering you won’t experience reduced effectiveness
because of your concurrent use of Nolvadex or from any sort of tolerance
developed by using other AIs on your cycle(9). There is also a decent
amount of preclinical data suggesting that Aromasin has a beneficial
effect on bone mineral metabolism that is not seen with
non-steroidal agents, and it may also have beneficial effects on lipid
metabolism that are not found in the non-steroidal Letro and
A-dex (9).
Finally, as we’re going to be using Nolvadex for PCT anyway, and we
ought to be using an AI with it for maximum recovery…I think Aromasin-
considering it’s compatibility with Nolvadex and beneficial effects on
bone mineral content and lipid profile, has finally stopped being the
black sheep of AIs and found a home in our cycles.
References:
- Clin Cancer Res. 2005 Apr 15;11(8):2809-21.
- 2. J Clin Endocrinol Metab. 1995
Sep;80(9):2658-60.
- [Clinical aspects of estrogen and bone
metabolism] Clin Calcium. 2002 Sep;12(9):1246-51. Japanese.
- Science, Vol 283, Issue 5406, 1277-1278 , 26 February 1999
- J Clin Endocrinol Metab 2000 Jul;85(7):2370-7, "Estrogen
Suppression in Males"
- Fertil Steril. 1978 Mar;29(3):320-7
- J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80
- .J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):85-91.
- The Oncologist, Vol. 9, No. 2, 126–136, April 2004
- Zilembo N., Noberasco C., Bajetta E., Martinetti A., Mariani L.,
Orefici S. Endocrinological and clinical evaluation of exemestane, a
new steroidal aromatase inhibitor. Br. J. Cancer, 72:
1007-1012, 1995
- Clinical Cancer Research Vol. 10, 1943-1948, March 2004
- The Journal of Clinical Endocrinology & Metabolism Vol. 88, No.
12 5951-5956
Copyright © 2003 by The Endocrine Society
|